20 November 2024 · 1 min read
This could be big: "Oura valued at $5B following deal with medical device firm Dexcom.
Oura's $5B valuation following its deal with Dexcom signals a powerful convergence of continuous glucose monitoring and consumer wearables — and I think it could be a game-changer for health optimization well beyond diabetic patients.
Author
Last updated
6 May 2026
This could be big: "Oura valued at $5B following deal with medical device firm Dexcom."
Wow. The convergence of two major trends - continuous glucose monitoring (CGM), which is gaining traction even beyond diabetic patients, and the rise of consumer-friendly wearables - is truly intriguing.
This could be a game-changer - not just for managing chronic conditions but for overall health optimization; I could definitely see myself adopting this.
What do you think? Are we on the brink of a new wave of wearable health tech that could finally make potentially clinical-grade insights mainstream?